Insulet acquires CE mark for integration of insulin pump with Abbott CGM

Insulet has secured a CE mark for integrating its Omnipod 5 insulin pump with Abbott’s Freestyle Libre 2 Plus continuous glucose monitor (CGM) sensor. This clearance positions Insulet to launch the integrated Type 1 diabetes solution in Europe in the first half of 2024, starting with phased releases in the UK and Netherlands. Both companies have highlighted the potential of insulin pump-CGM integration, seeing significant market opportunities.

The Omnipod 5 is a tubeless, wearable insulin pump offering an alternative to multiple daily injections. By integrating the pump with CGMs, Insulet has developed automated insulin delivery systems adjusting dosages based on real-time blood glucose levels, with updates every five minutes.

Initially integrating with Dexcom’s G6 CGM in 2022, Insulet has since worked to integrate with Abbott's devices. The CE mark covers integration with Abbott’s older Libre 2 device, with plans to include the newer Libre 3